Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer - Episode 4
Clinical Trial Considerations for eBC Treatment Selection
Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2– early-stage breast cancer (eBC) guide clinical decision-making, exploring real-world adherence to these guidelines, the complexity of risk stratification in various clinical scenarios, and the role of clinical factors, biomarkers, and advanced testing methodologies (including RSClin N+, next-generation sequencing [NGS], fluorescence in situ hybridization [FISH], immunohistochemistry [IHC], and circulating DNA [ctDNA]) in defining “high-risk” patients and guiding treatment strategies.
Video Player is loading.
Video content above is prompted by the following:
- How do you use adjuvant therapy in patients with HR+/HER2–eBC?
- How do risk factors impact your adjuvant treatment strategy?
- Which risk factors are most influential, and why?
- Please discuss some recent adjuvant CDK4/6 inhibitor studies in eBC:
- Abemaciclib + endocrine therapy
- Ribociclib + nonsteroidal aromatase inhibitor — Final analysis Node-negative (N0) subgroup analysis; NATALEE 4-y
- Palbociclib – analysis of the sensitivity to endocrine therapy assay in the PALLAS adjuvant trial of palbociclib Original PALLAS
- How do risk factors impact your adjuvant treatment strategy?
Related Content:
